Xeomin

Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

Xeomin Meets Primary Endpoint in Parallel Clinical Study

Xeomin Meets Primary Endpoint in Parallel Clinical Study

Merz Aesthetics has announced positive results from a post-market, parallel group clinical trial to evaluate the efficacy of Xeomin (incobotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines when compared to Botox Cosmetic (onabotulinumtoxinA, Allergan). The trial met its primary efficacy endpoint, defined as ≥ 1-point improvement from baseline on the Facial Wrinkle Scale (FWS) at maximum frown one month after a single treatment.

Skin Care: Xeomin

Main Image: 
Xeomin

Xeomin botulinum toxin type A is FDA approved for the treatment of moderate to severe glabella lines. The toxin comes in powder form and does not require refrigeration. In addition, the company employs a proprietary manufacturing process that isolates the therapeutic component of the toxin and removes the accessory proteins. Contact: 866.862.1211, www.merzusa.com.

No, don't share this with BeautyEtc
Article free tagging: